These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33499718)

  • 1. Cost-effectiveness of implementing 13-valent pneumococcal conjugate vaccine for U.S. adults aged 19 years and older with underlying conditions.
    Kobayashi M; Stoecker C; Xing W; Cho BH; Pilishvili T
    Hum Vaccin Immunother; 2021 Jul; 17(7):2232-2240. PubMed ID: 33499718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices.
    Matanock A; Lee G; Gierke R; Kobayashi M; Leidner A; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2019 Nov; 68(46):1069-1075. PubMed ID: 31751323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States.
    Stoecker C; Kim L; Gierke R; Pilishvili T
    J Gen Intern Med; 2016 Aug; 31(8):901-8. PubMed ID: 26976292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
    Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
    Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States.
    Prasad N; Stoecker C; Xing W; Cho BH; Leidner AJ; Kobayashi M
    Vaccine; 2023 May; 41(18):2914-2921. PubMed ID: 37012118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
    Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine.
    Gouveia M; Jesus G; Inês M; Costa J; Borges M
    Hum Vaccin Immunother; 2019; 15(4):850-858. PubMed ID: 30633615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.
    Choi MJ; Kang SO; Oh JJ; Park SB; Kim MJ; Cheong HJ
    Hum Vaccin Immunother; 2018; 14(8):1914-1922. PubMed ID: 29953307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program.
    Stoecker C; Kobayashi M; Matanock A; Cho BH; Pilishvili T
    Vaccine; 2020 Feb; 38(7):1770-1777. PubMed ID: 31889609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
    Smith KJ; Wateska AR; Nowalk MP; Raymund M; Nuorti JP; Zimmerman RK
    JAMA; 2012 Feb; 307(8):804-12. PubMed ID: 22357831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Tomczyk S; Bennett NM; Stoecker C; Gierke R; Moore MR; Whitney CG; Hadler S; Pilishvili T;
    MMWR Morb Mortal Wkly Rep; 2014 Sep; 63(37):822-5. PubMed ID: 25233284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years.
    Black CL; Williams WW; Warnock R; Pilishvili T; Kim D; Kelman JA
    MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(27):728-733. PubMed ID: 28704347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.
    Kobayashi M; Pilishvili T; Farrar JL; Leidner AJ; Gierke R; Prasad N; Moro P; Campos-Outcalt D; Morgan RL; Long SS; Poehling KA; Cohen AL
    MMWR Recomm Rep; 2023 Sep; 72(3):1-39. PubMed ID: 37669242
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study.
    Guo J; Zhang H; Zhang H; Lai X; Wang J; Feng H; Fang H
    Vaccine; 2023 Jan; 41(3):716-723. PubMed ID: 36522264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
    Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
    PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditions-United States.
    Ahmed SS; Pondo T; Xing W; McGee L; Farley M; Schaffner W; Thomas A; Reingold A; Harrison LH; Lynfield R; Rowlands J; Bennett N; Petit S; Barnes M; Smelser C; Beall B; Whitney CG; Pilishvili T
    Clin Infect Dis; 2020 Jun; 70(12):2484-2492. PubMed ID: 31402387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.
    Earnshaw SR; McDade CL; Zanotti G; Farkouh RA; Strutton D
    BMC Infect Dis; 2012 Apr; 12():101. PubMed ID: 22530841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.